|Systematic (IUPAC) name|
|Mol. mass||325.244 g/mol|
|(what is this?)|
Bromadoline (U-47931E) is an opioid analgesic selective for the mu-opioid receptor developed by the Upjohn company in the 1970s. The drug has a potency lying between that of codeine and morphine being slightly stronger than pentazocine. It is presumed that the (1R,2R) isomer is the active opioid, overlaying as it does with many other mu agonists. Bromadoline is related to AH-7921 and U-47700.
- Unlisted Drugs, volumes 34-35, page 392
- Hayes, A. G.; Skingle, M.; Tyers, M. B. (1987). "Evaluation of the receptor selectivities of opioid drugs by investigating the block of their effect on urine output by beta-funaltrexamine". The Journal of Pharmacology and Experimental Therapeutics 240 (3): 984–988. PMID 3559988.
- U.S. Patent 4,098,904
- 'Differential sensitivity of models of antinociception in the rat, mouse and guinea-pig to IL- and K-opioid receptor agonists' A.G. Hayes, M.J. Sheehan & M.B. Tyers - Br. J. Pharmac. (1987), 91, 823-832
- J Mol Model 'Insights into subtype selectivity of opioid agonists by ligand-based and structure-based methods' Jianxin Cheng & Guixia Liu & Jing Zhang & Zhejun Xu & Yun Tang
- 'Factors Affecting Binding of trans-N-[2-(Methylamino)cyclohexyl]benzamides at the Primary Morphine receptor' B. Vernon Cheney, Jacob Smuszkovicz, Robert A. Lahtr & Dominic A. Zichi - J Med Chem. 1985 Dec;28(12):1853-64.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|